Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.

@article{Schmitt2011CancerTT,
  title={Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.},
  author={Manfred Schmitt and Nadia Harbeck and Nils Bruenner and F. J{\"a}nicke and C. Meisner and Bernd Muehlenweg and Heike Jansen and Julia Dorn and Ulrike Anneliese Nitz and Eva Johanna Kantelhardt and Christoph Thomssen},
  journal={Expert review of molecular diagnostics},
  year={2011},
  volume={11 6},
  pages={617-34}
}
Clinical research on cancer biomarkers is essential in understanding recent discoveries in cancer biology and heterogeneity of the cancer disease. However, there are only a few examples of clinically useful studies that have identified cancer biomarkers with clinical benefit. Urokinase-type plasminogen activator (uPA) and its inhibitor plasminogen activator inhibitor type 1 (PAI-1) are two of the few tumor tissue-associated cancer biomarkers that have been evaluated successfully and extensively… CONTINUE READING
33 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 33 extracted citations

Similar Papers

Loading similar papers…